| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | 10-Q |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 |
| 30 Oct 2026 | SCHEDULE 13G |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) |
| 14 Oct 2026 | Proxy statement: special meeting on November 24, 2026 |
| 06 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies |
| 23 Sep 2026 | PRE 14A |
| 28 Aug 2026 | EFFECT |
| 28 Aug 2026 | 424B3 |
| 21 Aug 2026 | S-3 |
| 21 Aug 2026 |
Form 3: Camisasca Riccardo Paolo, Chief Medical Officer
No securities owned |
| 18 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation |
| 12 Aug 2026 | D |
| 07 Aug 2026 |
Form 4: Rubin Steven D, Director
Received 19,117 shares as a grant or award · Granted 76,773 Stock Option (right to buy) |
| 07 Aug 2026 |
Form 4: Malca Yonatan, Director
Received 22,815 shares as a grant or award |
| 07 Aug 2026 |
Form 4: Taitel Haya, Director
Received 20,790 shares as a grant or award |
| 07 Aug 2026 |
Form 4: Ellis Sean, Director
Received 20,034 shares as a grant or award · Granted 40,000 Stock Option (right to buy) |
| 07 Aug 2026 |
Form 4: Yaacov-Garbeli Dana, Chief Financial Officer
Granted 140,000 Stock Option (right to buy) |
| 07 Aug 2026 |
Form 4: Galitzer Hillel, Chief Operating Officer
Granted 200,000 Stock Option (right to buy) |
Loading...